Matthieu Guibert

Title: Matthieu Guibert: Innovator in Recombinant AAV Production

Introduction

Matthieu Guibert is a notable inventor based in Germantown, MD (US). He has made significant contributions to the field of biotechnology, particularly in the production of recombinant Adeno-Associated Virus (rAAV) particles. His innovative methods have the potential to enhance the efficiency of rAAV production, which is crucial for various therapeutic applications.

Latest Patents

Guibert holds a patent for a "Scalable method for recombinant AAV production." This patent outlines improved methods for producing rAAV particles. The method involves culturing cells capable of producing rAAV particles in the presence of a histone deacetylase (HDAC) inhibitor. Additionally, it may include an increased amount of a sodium salt to further enhance production efficiency. This patent represents a significant advancement in the field of gene therapy.

Career Highlights

Matthieu Guibert is associated with Regenxbio Inc., a company that focuses on gene therapy and the development of innovative treatments. His work at Regenxbio has positioned him as a key player in the biotechnology sector, contributing to the advancement of therapeutic solutions for various diseases.

Collaborations

Guibert has collaborated with notable colleagues, including Michael Gillmeister and Miguel Valle. These collaborations have fostered a productive environment for innovation and have contributed to the success of their projects.

Conclusion

Matthieu Guibert's contributions to the field of recombinant AAV production highlight his role as an innovator in biotechnology. His patent and work at Regenxbio Inc. demonstrate his commitment to advancing gene therapy solutions.